Fortress Biotech announced a 9% increase in total net revenue to $19.2 million for Q3 2026 compared to the previous year. The company fully repaid its $15 million credit facility in September 2026, eliminating parent-level debt. Fortress also licensed FB-607 for irritable bowel syndrome with diarrhea, currently in Phase 2 trials, with top-line data expected in late 2027. Partnered programs advanced, including Crystalys Therapeutics' $130 million Series B financing and new drug approvals generating royalty income, positioning Fortress for long-term shareholder value growth.
Fortress Biotech's recent corporate update comes as the health sector on Pluang shows broad gains, with 99 of 150 US health stocks rising as of Nov 13, 2026 19:41 WIB. Notable movers include Heron Therapeutics Inc (HRTX) up 5.80% at USD 0.35 with a typical hold time of 39 days and a nearly balanced Pluang order activity of 52% Sell to 48% Buy. MiniMed Group Inc. (MMED) and Citius Pharmaceuticals Inc (CTXR) saw declines of 4.90% and 4.21% respectively, with MMED priced at USD 17.00 and CTXR at USD 0.51, the latter showing a strong sell bias of 84% on Pluang.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
